Skip to main content

Geographic Atrophy

32
Pipeline Programs
23
Companies
50
Clinical Trials
8 recruiting
3
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
6
3
8
4
7
4
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
4100%
+ 39 programs with unclassified modality

On Market (3)

Approved therapies currently available

Apellis Pharmaceuticals
EMPAVELIApproved
pegcetacoplan
Apellis Pharmaceuticals
Complement Inhibitor [EPC]subcutaneous2021
25M Part D
Apellis Pharmaceuticals
SYFOVREApproved
pegcetacoplan
Apellis Pharmaceuticals
Complement Inhibitor [EPC]intravitreal2023
2M Part D
Astellas
IZERVAYApproved
avacincaptad pegol
Astellas
intravitreal2023
216K Part D

Competitive Landscape

23 companies ranked by most advanced pipeline stage

Apellis Pharmaceuticals
Apellis PharmaceuticalsAustralia - Hawthorn East
2 programs
1
1
pegcetacoplanPhase 35 trials
Geographic Atrophy Long-Terms Outcomes StudyN/A1 trial
Active Trials
NCT06499571Completed255Est. Jul 2023
NCT04729062Approved For Marketing
NCT07020832Recruiting320Est. Aug 2028
+3 more trials
Astellas
AstellasChina - Shenyang
1 program
1
IZERVAY(avacincaptad pegol)Phase 45 trials
Active Trials
NCT06970665Recruiting20Est. Jun 2027
NCT06779773Recruiting1,000Est. Jan 2030
NCT05536297Completed278Est. Apr 2025
+2 more trials
Genentech
GenentechCA - Oceanside
8 programs
4
1
1
LampalizumabPhase 3Monoclonal Antibody1 trial
LampalizumabPhase 2Monoclonal Antibody1 trial
FCFD4514SPhase 11 trial
RO7171009Phase 11 trial
RO7303359Phase 11 trial
+3 more programs
Active Trials
NCT05626114Recruiting60Est. Mar 2031
NCT02288559Completed96Est. Jun 2017
NCT00973011Completed18Est. Jul 2010
+5 more trials
Alcon
AlconFORT WORTH, TX
3 programs
2
1
AL-8309B Ophthalmic SolutionPhase 31 trial
Al-78898APhase 21 trial
CLG561Phase 2
Active Trials
NCT01603043Terminated10Est. Nov 2012
NCT00890097Terminated772Est. May 2012
Biocorp
BiocorpFrance - Issoire
3 programs
1
2
Avacincaptad PegolPhase 31 trial
TinlarebantPhase 31 trial
Avacincaptad PegolPhase 2/31 trial
Active Trials
NCT02686658Completed286Est. Apr 2020
NCT04435366Completed448Est. Aug 2023
NCT05949593Active Not Recruiting429Est. Aug 2027
Annexon Biosciences
Annexon BiosciencesCA - Brisbane
1 program
1
ANX007Phase 34 trials
Active Trials
NCT06510816Active Not Recruiting659Est. Oct 2027
NCT04656561Completed270Est. Sep 2023
NCT04188015Completed17Est. Jun 2019
+1 more trials
Belite Bio
Belite BioSAN DIEGO, CA
1 program
1
TinlarebantPhase 3
Kubota Vision
Kubota VisionJapan - Tokyo
2 programs
1
1
ACU-4429Phase 2/3
Emixustat HCl TabletPhase 11 trial
Active Trials
NCT02130531Completed26Est. Nov 2015
Kubota Pharmaceutical
1 program
1
ACU-4429Phase 2/31 trial
Active Trials
NCT01802866Completed508Est. May 2016
Otsuka
OtsukaJapan - Tokushima
1 program
1
ACU-4429Phase 2/3
NGM Biopharmaceuticals
2 programs
1
1
NGM621Phase 21 trial
NGM621Phase 11 trial
Active Trials
NCT04014777Completed15Est. May 2020
NCT04465955Completed320Est. Aug 2022
AbbVie
AbbVieNORTH CHICAGO, IL
2 programs
1
1
400 µg Brimonidine ImplantPhase 21 trial
ABBV-6628Phase 1/21 trial
Active Trials
NCT07160179Recruiting66Est. Oct 2029
NCT02087085Terminated310Est. Mar 2018
Sandoz
SandozAustria - Kundl
2 programs
2
CLG561Phase 21 trial
LFG316Phase 21 trial
Active Trials
NCT02515942Completed114Est. Dec 2017
NCT01527500Completed158Est. Jun 2015
ReVision Therapeutics
ReVision TherapeuticsNJ - Ridgewood
1 program
1
FenretinidePhase 21 trial
Active Trials
NCT00429936Completed245Est. May 2010
Inflammasome Therapeutics
1 program
1
K8Phase 1/21 trial
Active Trials
NCT06164587Active Not Recruiting30Est. Jun 2026
Ocugen
OcugenPA - Malvern
1 program
1
OCU410Phase 1/21 trial
Active Trials
NCT06018558Active Not Recruiting60Est. May 2026
Roche
RocheSTAVANGER NORWAY, Norway
4 programs
RO7303359PHASE_1
RO7669330PHASE_1
LampalizumabPHASE_3Monoclonal Antibody
LampalizumabPHASE_3Monoclonal Antibody
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
2 programs
Patients With Geographic Atrophy and Their Patient Journey in the United States (US)N/A1 trial
BI 771716PHASE_11 trial
Active Trials
NCT05891275Completed68,563Est. Dec 2023
NCT06006585Completed20Est. May 2024
IQVIA
IQVIADURHAM, NC
1 program
Geographic Atrophy Long-Terms Outcomes StudyN/A
Biolab Pharma
Biolab PharmaBrazil - São Paulo
1 program
postbioticsN/A1 trial
Active Trials
NCT05391074Unknown10Est. Jun 2024
Sanofi
SanofiPARIS, France
1 program
SAR446597PHASE_1_21 trial
Active Trials
NCT07215234Recruiting104Est. Jul 2032
Ionis Pharmaceuticals
1 program
IONIS-FB-LrxPHASE_21 trial
Active Trials
NCT03446144Withdrawn0Est. Oct 2018
Santen
SantenCA - Emeryville
1 program
SirolimusPHASE_21 trial
Active Trials
NCT01675947Terminated52Est. Feb 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Astellasavacincaptad pegol
Apellis Pharmaceuticalspegcetacoplan
Apellis Pharmaceuticalspegcetacoplan
Annexon BiosciencesANX007
BiocorpTinlarebant
Apellis Pharmaceuticalspegcetacoplan
Astellasavacincaptad pegol
Apellis Pharmaceuticalspegcetacoplan
Apellis Pharmaceuticalspegcetacoplan
BiocorpAvacincaptad Pegol
Apellis Pharmaceuticalspegcetacoplan
Apellis Pharmaceuticalspegcetacoplan
Apellis Pharmaceuticalspegcetacoplan
GenentechLampalizumab
AlconAL-8309B Ophthalmic Solution

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 9,343 patients across 50 trials

NCT06970665Astellasavacincaptad pegol

A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration

Start: Jul 2025Est. completion: Jun 202720 patients
Phase 4Recruiting

A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation

Start: Feb 2026Est. completion: Aug 2028320 patients
Phase 3Recruiting

Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe

Start: Oct 2025Est. completion: Dec 202544 patients
Phase 3Completed

A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Geographic Atrophy (GA)

Start: Jul 2024Est. completion: Oct 2027659 patients
Phase 3Active Not Recruiting

Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy

Start: Jul 2023Est. completion: Aug 2027429 patients
Phase 3Active Not Recruiting

An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

Start: May 2023Est. completion: Jul 2027100 patients
Phase 3Active Not Recruiting
NCT05536297Astellasavacincaptad pegol

Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy

Start: Sep 2022Est. completion: Apr 2025278 patients
Phase 3Completed

Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

Start: Nov 2021Est. completion: Jan 2025124 patients
Phase 3Completed

An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD

Start: Mar 2021Est. completion: Sep 2025792 patients
Phase 3Completed
NCT04435366BiocorpAvacincaptad Pegol

A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)

Start: Jun 2020Est. completion: Aug 2023448 patients
Phase 3Completed

A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With PNH

Start: Aug 2019Est. completion: Jun 202153 patients
Phase 3Completed

Pegcetacoplan Long Term Safety and Efficacy Extension Study

Start: Aug 2018Est. completion: Jul 2026160 patients
Phase 3Active Not Recruiting

Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Start: Jun 2018Est. completion: Aug 202080 patients
Phase 3Completed

Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)

Start: Jul 2016Est. completion: Jan 2018994 patients
Phase 3Terminated
NCT00890097AlconAL-8309B Ophthalmic Solution

Geographic Atrophy Treatment Evaluation

Start: Apr 2009Est. completion: May 2012772 patients
Phase 3Terminated
NCT02686658BiocorpAvacincaptad Pegol

Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Start: Dec 2015Est. completion: Apr 2020286 patients
Phase 2/3Completed

Safety and Efficacy Assessment Treatment Trials of Emixustat Hydrochloride

Start: Feb 2013Est. completion: May 2016508 patients
Phase 2/3Completed

A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio

Start: Jun 2025Est. completion: Nov 2027240 patients
Phase 2Recruiting

A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251

Start: Mar 2023Est. completion: Mar 203160 patients
Phase 2Recruiting

A Study of Pegcetacoplan for Patients With Transplant-associated Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplantation

Start: Feb 2022Est. completion: Dec 202412 patients
Phase 2Completed

Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN

Start: Sep 2021Est. completion: Jan 202613 patients
Phase 2Completed

A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy

Start: Feb 2021Est. completion: Sep 2023270 patients
Phase 2Completed

A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Start: Feb 2021Est. completion: Dec 202812 patients
Phase 2Recruiting

MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)

Start: Sep 2020Est. completion: Jul 2023249 patients
Phase 2Terminated

A Study of NGM621 in Participants With Geographic Atrophy

Start: Jul 2020Est. completion: Aug 2022320 patients
Phase 2Completed

A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNH

Start: Aug 2018Est. completion: Oct 20194 patients
Phase 2Completed

Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

Start: Mar 2018Est. completion: Oct 20180
Phase 2Withdrawn
NCT03364153Astellasavacincaptad pegol

Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)

Start: Jan 2018Est. completion: Mar 2025121 patients
Phase 2Completed
NCT03362190Astellasavacincaptad pegol

ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)

Start: Oct 2017Est. completion: Oct 201864 patients
Phase 2Completed

CLG561 Proof-of-Concept Study as a Monotherapy and in Combination With LFG316 in Subjects With Geographic Atrophy (GA)

Start: Sep 2015Est. completion: Dec 2017114 patients
Phase 2Completed

Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy

Start: Sep 2015Est. completion: Jan 2018246 patients
Phase 2Completed

A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy

Start: Mar 2015Est. completion: Jun 201796 patients
Phase 2Completed
NCT02397954Astellasavacincaptad pegol

A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)

Start: Mar 2015Est. completion: Oct 20154 patients
Phase 2Completed
NCT02087085AbbVie400 µg Brimonidine Implant

A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration

Start: May 2014Est. completion: Mar 2018310 patients
Phase 2Terminated

A Multicenter, Proof-Of-Concept Study Of Intravitreal AL-78898A In Patients With Geographic Atrophy (GA) Associated With Age-Related Macular Degeneration (AMD)

Start: Jun 2012Est. completion: Nov 201210 patients
Phase 2Terminated

An Extension Study to Evaluate the Long-Term Safety of Lampalizumab in Participants With Geographic Atrophy

Start: May 2012Est. completion: Feb 2018159 patients
Phase 2Terminated

Intravitreal Injections of Sirolimus in the Treatment of Geographic Atrophy

Start: Feb 2012Est. completion: Feb 201652 patients
Phase 2Terminated

Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)

Start: Jan 2012Est. completion: Jun 2015158 patients
Phase 2Completed

Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration

Start: Dec 2006Est. completion: May 2010245 patients
Phase 2Completed

A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

Start: Oct 2025Est. completion: Jul 2032104 patients
Phase 1/2Recruiting

Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Start: Aug 2025Est. completion: Oct 202966 patients
Phase 1/2Recruiting

Evaluation of Kamuvudine-8 in Subjects With Geographic Atrophy

Start: Apr 2024Est. completion: Jun 202630 patients
Phase 1/2Active Not Recruiting

Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy

Start: Feb 2023Est. completion: May 202660 patients
Phase 1/2Active Not Recruiting

Pegcetacoplan (APL-2) in Neovascular AMD

Start: Feb 2018Est. completion: Apr 201917 patients
Phase 1/2Terminated

A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Start: Jul 2025Est. completion: Jan 2027132 patients
Phase 1Recruiting

A Study to Test How Well Different Doses of BI 771716 Are Tolerated by People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

Start: Oct 2023Est. completion: May 202420 patients
Phase 1Completed

A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of RO7303359 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

Start: Dec 2020Est. completion: Jan 202337 patients
Phase 1Completed

Study of NGM621 in Participants With Geographic Atrophy

Start: Jul 2019Est. completion: May 202015 patients
Phase 1Completed

Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With Geographic Atrophy

Start: Nov 2018Est. completion: Apr 202119 patients
Phase 1Completed

Study of ANX007 in Participants With Primary Open-angle Glaucoma

Start: Jul 2018Est. completion: Jun 201917 patients
Phase 1Completed

Related Jobs

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

7 late-stage (Phase 3) programs, potential near-term approvals
8 actively recruiting trials targeting 9,343 patients
23 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.